{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:03:14Z","timestamp":1791352994264,"version":"4.3.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1038\/nrrheum.2011.61","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T10:13:03Z","timestamp":1305022383000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Intravenous immunoglobulin therapy in rheumatic diseases"],"prefix":"10.1038","volume":"7","author":[{"given":"Jagadeesh","family":"Bayry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vir Singh","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini V.","family":"Kaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,10]]},"reference":[{"key":"BFnrrheum201161_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine, M. D. & Kaveri, S. V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345, 747\u2013755 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR2","doi-asserted-by":"crossref","unstructured":"Galeotti, C., Bayry, J., Kone-Paut, I. & Kaveri, S. V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun. Rev. 9, 441\u2013448 (2010).","DOI":"10.1016\/j.autrev.2009.12.004"},{"key":"BFnrrheum201161_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1161\/01.CIR.94.6.1379","volume":"94","author":"H Kato","year":"1996","unstructured":"Kato, H.  et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94, 1379\u20131385 (1996).","journal-title":"Circulation"},{"key":"BFnrrheum201161_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1086\/430953","volume":"192","author":"JC Burns","year":"2005","unstructured":"Burns, J. C.  et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 192, 344\u2013349 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFnrrheum201161_CR5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger, J. W.  et al. A single intravenous infusion of \u03b3-globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324, 1633\u20131639 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR6","doi-asserted-by":"crossref","unstructured":"Oates-Whitehead, R. M.  et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews, Issue 4. Art. No.:CD004000. doi: 10.1002\/14651858.CD004000 (2003).","DOI":"10.1002\/14651858.CD004000"},{"key":"BFnrrheum201161_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1011039216251","volume":"21","author":"M Gupta","year":"2001","unstructured":"Gupta, M.  et al. Cytokine modulation with immune \u03b3-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 21, 193\u2013199 (2001).","journal-title":"J. Clin. Immunol."},{"key":"BFnrrheum201161_CR8","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1542\/peds.111.2.e140","volume":"111","author":"CL Wang","year":"2003","unstructured":"Wang, C. L.  et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 111, E140\u2013E147 (2003).","journal-title":"Pediatrics"},{"key":"BFnrrheum201161_CR9","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.4049\/jimmunol.174.9.5837","volume":"174","author":"J Abe","year":"2005","unstructured":"Abe, J.  et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 174, 5837\u20135845 (2005).","journal-title":"J. Immunol."},{"key":"BFnrrheum201161_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490\u2013500 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum201161_CR11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2353\/ajpath.2009.080987","volume":"174","author":"S Andre","year":"2009","unstructured":"Andre, S., Tough, D. F., Lacroix-Desmazes, S., Kaveri, S. V. & Bayry, J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am. J. Pathol. 174, 1575\u20131587 (2009).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum201161_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrrheum.2009.183","volume":"5","author":"JH Esensten","year":"2009","unstructured":"Esensten, J. H., Wofsy, D. & Bluestone, J. A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 560\u2013565 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2009.77","volume":"5","author":"J Bayry","year":"2009","unstructured":"Bayry, J. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat. Rev. Rheumatol. 5, 244\u2013245 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrrheum.2009.80","volume":"5","author":"F Annunziato","year":"2009","unstructured":"Annunziato, F., Cosmi, L., Liotta, F., Maggi, E. & Romagnani, S. Type 17 T helper cells\u2014origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 5, 325\u2013331 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl. 57","key":"BFnrrheum201161_CR15","first-page":"93","volume":"28","author":"B Olivito","year":"2010","unstructured":"Olivito, B.  et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin. Exp. Rheumatol. 28 (Suppl. 57), 93\u201397 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201161_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2249.2010.04236.x","volume":"162","author":"S Jia","year":"2010","unstructured":"Jia, S., Li, C., Wang, G., Yang, J. & Zu, Y. The T helper type 17\/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin. Exp. Immunol. 162, 131\u2013137 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201161_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","volume":"111","author":"A Ephrem","year":"2008","unstructured":"Ephrem, A.  et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111, 715\u2013722 (2008).","journal-title":"Blood"},{"key":"BFnrrheum201161_CR18","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","volume":"179","author":"A Kessel","year":"2007","unstructured":"Kessel, A.  et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179, 5571\u20135575 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum201161_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","volume":"127","author":"MS Maddur","year":"2011","unstructured":"Maddur, M. S.  et al. Inhibition of differentiation, amplification and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127, 823\u2013830 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl.","key":"BFnrrheum201161_CR20","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange, J. S.  et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117 (Suppl.), S525\u2013S553 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201161_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpeds.2007.12.021","volume":"153","author":"AH Tremoulet","year":"2008","unstructured":"Tremoulet, A. H.  et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J. Pediatr. 153, 117\u2013121 (2008).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201161_CR22","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaci.2008.09.011","volume":"122","author":"J Abe","year":"2008","unstructured":"Abe, J.  et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J. Allergy Clin. Immunol. 122, 1008\u20131013 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201161_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.humimm.2010.06.008","volume":"71","author":"W Fury","year":"2010","unstructured":"Fury, W.  et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum. Immunol. 71, 865\u2013873 (2010).","journal-title":"Hum. Immunol."},{"key":"BFnrrheum201161_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","volume":"146","author":"JC Burns","year":"2005","unstructured":"Burns, J. C.  et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 146, 662\u2013667 (2005).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201161_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","volume":"23","author":"LG Rider","year":"1997","unstructured":"Rider, L. G. & Miller, F. W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 23, 619\u2013655 (1997).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrrheum201161_CR26","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/art.10566","volume":"46","author":"M Massa","year":"2002","unstructured":"Massa, M.  et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 46, 3015\u20133025 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/adc.72.1.25","volume":"72","author":"A Sansome","year":"1995","unstructured":"Sansome, A. & Dubowitz, V. Intravenous immunoglobulin in juvenile dermatomyositis\u2014four year review of nine cases. Arch. Dis. Child. 72, 25\u201328 (1995).","journal-title":"Arch. Dis. Child."},{"key":"BFnrrheum201161_CR28","first-page":"2498","volume":"27","author":"SM Al-Mayouf","year":"2000","unstructured":"Al-Mayouf, S. M., Laxer, R. M., Schneider, R., Silverman, E. D. & Feldman, B. M. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 27, 2498\u20132503 (2000).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201161_CR29","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"Donofrio, P. D.  et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40, 890\u2013900 (2009).","journal-title":"Muscle Nerve"},{"key":"BFnrrheum201161_CR30","first-page":"603","volume":"8","author":"AM Prieur","year":"1990","unstructured":"Prieur, A. M.  et al. High dose immunoglobulin therapy in severe juvenile chronic\tarthritis: long-term follow-up in 16 patients. Clin. Exp. Rheumatol. 8, 603\u2013608 (1990).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201161_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/art.1780330714","volume":"33","author":"ED Silverman","year":"1990","unstructured":"Silverman, E. D.  et al. Intravenous \u03b3 globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 33, 1015\u20131022 (1990).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR32","first-page":"2353","volume":"21","author":"ED Silverman","year":"1994","unstructured":"Silverman, E. D.  et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J. Rheumatol. 21, 2353\u20132358 (1994).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201161_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578\u2013582 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/00002281-200311000-00006","volume":"15","author":"B Santmyire-Rosenberger","year":"2003","unstructured":"Santmyire-Rosenberger, B. & Dugan, E. M. Skin involvement in dermatomyositis. Curr. Opin. Rheumatol. 15, 714\u2013722 (2003).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201161_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","volume":"6","author":"MC Dalakas","year":"2010","unstructured":"Dalakas, M. C. Immunotherapy of myositis: issues, concerns and future prospects. Nat. Rev. Rheumatol. 6, 129\u2013137 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/art.11428","volume":"50","author":"G Page","year":"2004","unstructured":"Page, G., Chevrel, G. & Miossec, P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and TH1 cytokine-producing cells. Arthritis Rheum. 50, 199\u2013208 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/ar2139","volume":"9","author":"C Grundtman","year":"2007","unstructured":"Grundtman, C., Malmstrom, V. & Lundberg, I. E. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res. Ther. 9, 208 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201161_CR38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas, M. C.  et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993\u20132000 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya, K., Semino-Mora, C., Granger, R. P. & Dalakas, M. C. Downregulation of TGF-\u03b21 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin. Immunol. 94, 99\u2013104 (2000).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum201161_CR40","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju, R. & Dalakas, M. C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128, 1887\u20131896 (2005).","journal-title":"Brain"},{"key":"BFnrrheum201161_CR41","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729\u20131735 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201161_CR42","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2006.058644","volume":"66","author":"S Barbasso Helmers","year":"2007","unstructured":"Barbasso Helmers, S.  et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann. Rheum. Dis. 66, 1276\u20131283 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201161_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","volume":"46","author":"A Tournadre","year":"2009","unstructured":"Tournadre, A.  et al. TH1 and TH17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 46, 297\u2013301 (2009).","journal-title":"Cytokine"},{"key":"BFnrrheum201161_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara, I.  et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893\u2013908 (2008).","journal-title":"Eur. J. Neurol."},{"key":"BFnrrheum201161_CR45","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/acr.20325","volume":"62","author":"I Marie","year":"2010","unstructured":"Marie, I.  et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. (Hoboken) 62, 1748\u20131755 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"Suppl. 2","key":"BFnrrheum201161_CR46","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.jaci.2009.10.067","volume":"125","author":"A Joseph","year":"2010","unstructured":"Joseph, A.  et al. Immunologic rheumatic disorders. J. Allergy Clin. Immunol. 125 (Suppl. 2), S204\u2013S215 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201161_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","volume":"91","author":"P Cherin","year":"1991","unstructured":"Cherin, P.  et al. Efficacy of intravenous \u03b3-globulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am. J. Med. 91, 162\u2013168 (1991).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201161_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin, P.  et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46, 467\u2013474 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR49","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas, M. C.  et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48, 712\u2013716 (1997).","journal-title":"Neurology"},{"key":"BFnrrheum201161_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter, M. C.  et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22\u201328 (2000).","journal-title":"J. Neurol."},{"key":"BFnrrheum201161_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrrheum.2010.158","volume":"6","author":"M Chen","year":"2010","unstructured":"Chen, M. & Kallenberg, C. G. ANCA-associated vasculitides\u2014advances in pathogenesis and treatment. Nat. Rev. Rheumatol. 6, 653\u2013664 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","volume":"101","author":"C Richter","year":"1995","unstructured":"Richter, C.  et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. 101, 2\u20137 (1995).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201161_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne, D. R.  et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433\u2013439 (2000).","journal-title":"QJM"},{"key":"BFnrrheum201161_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"V Martinez","year":"2008","unstructured":"Martinez, V.  et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 58, 308\u2013317 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR55","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMra071297","volume":"358","author":"A Rahman","year":"2008","unstructured":"Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929\u2013939 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.2159","volume":"16","author":"N Charles","year":"2010","unstructured":"Charles, N., Hardwick, D., Daugas, E., Illei, G. G. & Rivera, J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat. Med. 16, 701\u2013707 (2010).","journal-title":"Nat. Med."},{"key":"BFnrrheum201161_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molmed.2009.12.005","volume":"16","author":"JC Crisp\u00edn","year":"2010","unstructured":"Crisp\u00edn, J. C.  et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16, 47\u201357 (2010).","journal-title":"Trends Mol. Med."},{"key":"BFnrrheum201161_CR58","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMcibr1006936","volume":"363","author":"SV Kaveri","year":"2010","unstructured":"Kaveri, S. V., Mouthon, L. & Bayry, J. Basophils and nephritis in lupus. N. Engl. J. Med. 363, 1080\u20131082 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrrheum.2010.60","volume":"6","author":"JC Crisp\u00edn","year":"2010","unstructured":"Crisp\u00edn, J. C., Kyttaris, V. C., Terhorst, C. & Tsokos, G. C. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 317\u2013325 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","volume":"66","author":"E Toubi","year":"2005","unstructured":"Toubi, E., Kessel, A. & Shoenfeld, Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol. 66, 395\u2013402 (2005).","journal-title":"Hum. Immunol."},{"key":"BFnrrheum201161_CR61","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/ard.2006.058784","volume":"66","author":"D Micheloud","year":"2007","unstructured":"Micheloud, D., Calder\u00f3n, M., Caparrros, M. & D'Cruz, D. P. Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann. Rheum. Dis. 66, 986\u2013987 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201161_CR62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","volume":"354","author":"JN Boletis","year":"1999","unstructured":"Boletis, J. N., Ioannidis, J. P., Boki, K. A. & Moutsopoulos, H. M. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354, 569\u2013570 (1999).","journal-title":"Lancet"},{"key":"BFnrrheum201161_CR63","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","volume":"14","author":"Y Shoenfeld","year":"2002","unstructured":"Shoenfeld, Y.  et al. Efficacy of IVIg affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14, 1303\u20131311 (2002).","journal-title":"Int. Immunol."},{"key":"BFnrrheum201161_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/icb.2009.36","volume":"87","author":"KA Nikolova","year":"2009","unstructured":"Nikolova, K. A., Tchorbanov, A. I., Djoumerska-Alexieva, I. K., Nikolova, M. & Vassilev, T. L. Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc\u03b3IIB receptor on B cells. Immunol. Cell Biol. 87, 529\u2013533 (2009).","journal-title":"Immunol. Cell Biol."},{"key":"BFnrrheum201161_CR65","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","volume":"29","author":"T Tha-In","year":"2008","unstructured":"Tha-In, T., Bayry, J., Metselaar, H. J., Kaveri, S. V. & Kwekkeboom, J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29, 608\u2013615 (2008).","journal-title":"Trends Immunol."},{"key":"BFnrrheum201161_CR66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","volume":"7","author":"JF Seite","year":"2008","unstructured":"Seite, J. F., Shoenfeld, Y., Youinou, P. & Hillion, S. What is the contents of the magic draft IVIg? Autoimmun. Rev. 7, 435\u2013439 (2008).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201161_CR67","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1002\/art.11346","volume":"48","author":"J Bayry","year":"2003","unstructured":"Bayry, J.  et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-\u03b1 present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48, 3497\u20133502 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR68","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nrrheum.2010.47","volume":"6","author":"G Espinosa","year":"2010","unstructured":"Espinosa, G. & Cervera, R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat. Rev. Rheumatol. 6, 296\u2013300 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(88)92859-0","volume":"2","author":"LD Carreras","year":"1988","unstructured":"Carreras, L. D., Perez, G. N., Vega, H. R. & Casavilla, F. Lupus anticoagulant and recurrent fetal loss: successful treatment with \u03b3-globulin. Lancet 2, 393\u2013394 (1988).","journal-title":"Lancet"},{"key":"BFnrrheum201161_CR70","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0002-9378(00)70500-X","volume":"182","author":"DW Branch","year":"2000","unstructured":"Branch, D. W.  et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am. J. Obstet. Gynecol. 182, 122\u2013127 (2000).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"BFnrrheum201161_CR71","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00124743-200110000-00017","volume":"7","author":"GR Hsiao","year":"2001","unstructured":"Hsiao, G. R., Wolf, R. E. & Kimpel, D. L. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J. Clin. Rheumatol. 7, 336\u2013339 (2001).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum201161_CR72","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/intimm\/dxm052","volume":"19","author":"M Blank","year":"2007","unstructured":"Blank, M.  et al. The efficacy of specific IVIg anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19, 857\u2013865 (2007).","journal-title":"Int. Immunol."},{"key":"BFnrrheum201161_CR73","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/1529-0131(200104)44:4<876::AID-ANR144>3.0.CO;2-2","volume":"44","author":"SS Pierangeli","year":"2001","unstructured":"Pierangeli, S. S., Espinola, R., Liu, X., Harris, E. N. & Salmon, J. E. Identification of an Fc \u03b3 receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum. 44, 876\u2013883 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR74","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1600-0897.1998.tb00394.x","volume":"40","author":"G Sher","year":"1998","unstructured":"Sher, G.  et al. The selective use of heparin\/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am. J. Reprod. Immunol. 40, 74\u201382 (1998).","journal-title":"Am. J. Reprod. Immunol."},{"key":"BFnrrheum201161_CR75","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/0885066606287041","volume":"21","author":"SK Vora","year":"2006","unstructured":"Vora, S. K., Asherson, R. A. & Erkan, D. Catastrophic antiphospholipid syndrome. J. Intensive Care Med. 21, 144\u2013159 (2006).","journal-title":"J. Intensive Care Med."},{"key":"BFnrrheum201161_CR76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","volume":"32","author":"R Cervera","year":"2009","unstructured":"Cervera, R.  et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry\u201d. J. Autoimmun. 32, 240\u2013245 (2009).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum201161_CR77","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrrheum.2010.102","volume":"6","author":"M Trojanowska","year":"2010","unstructured":"Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 453\u2013460 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201161_CR78","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/ard.2006.060111","volume":"66","author":"F Nacci","year":"2007","unstructured":"Nacci, F.  et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann. Rheum. Dis. 66, 977\u2013979 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201161_CR79","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy, Y.  et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 50, 1005\u20131007 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR80","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","volume":"28","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz, Z.  et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin. Rheumatol. 28, 347\u2013350 (2009).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201161_CR81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.62.2.175","volume":"62","author":"H Amital","year":"2003","unstructured":"Amital, H.  et al. Fibrosis regression induced by intravenous \u03b3-globulin treatment. Ann. Rheum. Dis. 62, 175\u2013177 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201161_CR82","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas, M. C.  et al. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345, 1870\u20131876 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR83","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1212\/01.WNL.0000046680.47883.7D","volume":"60","author":"Y Takahashi","year":"2003","unstructured":"Takahashi, Y., Takata, T., Hoshino, M., Sakurai, M. & Kanazawa, I. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sj\u00f6gren's syndrome. IV immunoglobulin. Neurology 60, 503\u2013505 (2003).","journal-title":"Neurology"},{"key":"BFnrrheum201161_CR84","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/art.10716","volume":"48","author":"R Kaaja","year":"2003","unstructured":"Kaaja, R. & Julkunen, H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon  et al. Arthritis Rheum. 48, 280\u2013281 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201161_CR85","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670\u2013673 (2006).","journal-title":"Science"},{"key":"BFnrrheum201161_CR86","doi-asserted-by":"publisher","first-page":"19571","DOI":"10.1073\/pnas.0810163105","volume":"105","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIg. Proc. Natl Acad. Sci. USA 105, 19571\u201319578 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201161_CR87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","volume":"359","author":"SV Kaveri","year":"2008","unstructured":"Kaveri, S. V., Lacroix-Desmazes, S. & Bayry, J. The antiinflammatory IgG. N. Engl. J. Med. 359, 307\u2013309 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR88","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","volume":"26","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513\u2013533 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum201161_CR89","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","volume":"127","author":"M Ballow","year":"2011","unstructured":"Ballow, M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315\u2013323 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201161_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","volume":"98","author":"M Radosevich","year":"2010","unstructured":"Radosevich, M. & Burnouf, T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 98, 12\u201328 (2010).","journal-title":"Vox Sang."},{"key":"BFnrrheum201161_CR91","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz, U., Achiron, A., Sherer, Y. & Shoenfeld, Y. Safety of intravenous immunoglobulin (IVIg) therapy. Autoimmun. Rev. 6, 257\u2013259 (2007).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201161_CR92","first-page":"1","volume-title":"Clinical Focus on Primary Immune Deficiencies","author":"M Berger","year":"2008","unstructured":"Berger, M. in Clinical Focus on Primary Immune Deficiencies (ed. Sullivan, K.) Subcutaneous IgG therapy in immune deficiency diseases. Issue 13, 1\u201312 (Immune Deficiency Foundation, Townson, 2008)."},{"key":"BFnrrheum201161_CR93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.autrev.2010.03.003","volume":"9","author":"HM G\u00fcrcan","year":"2010","unstructured":"G\u00fcrcan, H. M., Keskin, D. B. & Ahmed, A. R. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun. Rev. 9, 553\u2013559 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201161_CR94","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli, M. G., Pettinari, L., Moretti, R., Logullo, F. & Gabrielli, A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev. 10, 144\u2013149 (2011).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201161_CR95","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo, E. D., Hansen, R. J. & Balthasar, J. P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645\u20132668 (2004).","journal-title":"J. Pharm. Sci."},{"key":"BFnrrheum201161_CR96","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","volume":"93","author":"RP Junghans","year":"1996","unstructured":"Junghans, R. P. & Anderson, C. L. The protection receptor for IgG catabolism is the \u03b22-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl Acad. Sci. USA 93, 5512\u20135516 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201161_CR97","first-page":"1","volume-title":"Intravenous Immunoglobulins in Clinical Practice","author":"A Morell","year":"1997","unstructured":"Morell, A. in Intravenous Immunoglobulins in Clinical Practice (eds. Lee, M. E. & Strand, V.) Ch. 1, Pharmacokinetics of intravenous immunoglobulin preparations. 1\u201318 (Marcel Dekker Inc., New York, 1997)."},{"key":"BFnrrheum201161_CR98","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"FA Bonilla","year":"2008","unstructured":"Bonilla, F. A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. North Am. 28, 803\u2013819 (2008).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"BFnrrheum201161_CR99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2249.2008.03620.x","volume":"152","author":"R Gustafson","year":"2008","unstructured":"Gustafson, R.  et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin. Exp. Immunol. 152, 274\u2013279 (2008).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201161_CR100","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach, P.  et al. High-dose intravenous \u03b3-globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228\u20131231 (1981).","journal-title":"Lancet"},{"key":"BFnrrheum201161_CR101","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","volume":"344","author":"V Blanchette","year":"1994","unstructured":"Blanchette, V.  et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344, 703\u2013707 (1994).","journal-title":"Lancet"},{"key":"BFnrrheum201161_CR102","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes, R. A.  et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136\u2013144 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrrheum201161_CR103","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ncpneuro0429","volume":"3","author":"J Bayry","year":"2007","unstructured":"Bayry, J., Kazatchkine, M. D. & Kaveri, S. V. Shortage of human intravenous immunoglobulin\u2014reasons and possible solutions. Nat. Clin. Pract. Neurol. 3, 120\u2013121 (2007).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrrheum201161_CR104","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"AR Ahmed","year":"2006","unstructured":"Ahmed, A. R., Spigelman, Z., Cavacini, L. A. & Posner, M. R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772\u20131779 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo, A. A.  et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242\u2013251 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201161_CR106","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncprheum0481","volume":"3","author":"J Bayry","year":"2007","unstructured":"Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D. & Kaveri, S. V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3, 262\u2013272 (2007).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum201161_CR107","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1177\/0961203306070970","volume":"15","author":"D Micheloud","year":"2006","unstructured":"Micheloud, D.  et al. Efficacy and safety of etanercept, high-dose intravenous \u03b3-globulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 15, 881\u2013885 (2006).","journal-title":"Lupus"},{"key":"BFnrrheum201161_CR108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s100670170107","volume":"20","author":"DK Chang","year":"2001","unstructured":"Chang, D. K.  et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin. Rheumatol. 20, 63\u201366 (2001).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201161_CR109","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00007611-199508000-00018","volume":"88","author":"C Saadeh","year":"1995","unstructured":"Saadeh, C., Bridges, W. & Burwick, F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South. Med. J. 88, 866\u2013870 (1995).","journal-title":"South. Med. J."},{"key":"BFnrrheum201161_CR110","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli, M. G.  et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun. Rev. 9, 124\u2013127 (2009).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201161_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trim.2010.04.009","volume":"23","author":"KG Sharma","year":"2010","unstructured":"Sharma, K. G.  et al. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transpl. Immunol. 23, 117\u2013120 (2010).","journal-title":"Transpl. Immunol."},{"key":"BFnrrheum201161_CR112","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M.  et al. Recapitulation of IVIg anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373\u2013376 (2008).","journal-title":"Science"},{"key":"BFnrrheum201161_CR113","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood.V90.10.4004","volume":"90","author":"V Hurez","year":"1997","unstructured":"Hurez, V.  et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90, 4004\u20134013 (1997).","journal-title":"Blood"},{"key":"BFnrrheum201161_CR114","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.4049\/jimmunol.180.4.2669","volume":"180","author":"Y Kanamaru","year":"2008","unstructured":"Kanamaru, Y.  et al. Inhibitory ITAM signaling by Fc \u03b1 RI-FcR \u03b3 chain controls multiple activating responses and prevents renal inflammation. J. Immunol. 180, 2669\u20132678 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum201161_CR115","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","volume":"133","author":"VM Brennan","year":"2003","unstructured":"Brennan, V. M., Salom\u00e9-Bentley, N. J. & Chapel, H. M. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin. Exp. Immunol. 133, 247\u2013251 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201161_CR116","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","volume":"60","author":"JB Caress","year":"2003","unstructured":"Caress, J. B., Cartwright, M. S., Donofrio, P. D. & Peacock, J. E. Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60, 1822\u20131824 (2003).","journal-title":"Neurology"},{"key":"BFnrrheum201161_CR117","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","volume":"6","author":"DJ Hamrock","year":"2006","unstructured":"Hamrock, D. J. Adverse events associated with intravenous immunoglobulin therapy. Int. Immunopharmacol. 6, 535\u2013542 (2006).","journal-title":"Int. Immunopharmacol."},{"key":"BFnrrheum201161_CR118","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.transci.2004.05.007","volume":"32","author":"FJ Achermann","year":"2005","unstructured":"Achermann, F. J., Julmy, F., Gilliver, L. G., Carrel, T. P. & Nydegger, U. E. Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype. Transfus. Apher. Sci. 32, 255\u2013262 (2005).","journal-title":"Transfus. Apher. Sci."},{"key":"BFnrrheum201161_CR119","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1182\/blood-2005-12-019604","volume":"109","author":"S Jarius","year":"2007","unstructured":"Jarius, S.  et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNF\u03b1-dependent and Fc-receptor-independent way. Blood 109, 4376\u20134382 (2007).","journal-title":"Blood"},{"key":"BFnrrheum201161_CR120","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaci.2009.07.051","volume":"124","author":"SH Desai","year":"2009","unstructured":"Desai, S. H., Chouksey, A., Poll, J. & Berger, M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J. Allergy Clin. Immunol. 124, 854\u2013856 (2009).","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.61.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.61","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.61.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:04:25Z","timestamp":1659171865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2011.61"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BFnrrheum201161"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2011.61","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]},"assertion":[{"value":"10 May 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research activities of J. Bayry and S. V. Kaveri are supported by grants from Laboratoire Fran\u00e7ais du Fractionnement et des Biotechnologies, Octapharma, Talecris and CSL Behring.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}